TLC Provides Corporate Update at Investor Conference – Dec 18, 2020
The Pharma Data
DECEMBER 17, 2020
Patient enrollment of EXCELLENCE pivotal trial reaches 98%. The trial remains on-track to complete enrollment of all 500 patients in the United States and Australia before the end of 2020, despite the worsening of the COVID-19 pandemic. The Phase I clinical trial is ongoing in Taiwan in Australia, with results expected in 2021.
40 
Let's personalize your content